Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary Objective:
- to assess the pathological Complete Response (pCR) rate in the breast of patients treated in following combinations: SAR240550 twice-weekly + weekly paclitaxel, SAR240550 weekly+ weekly paclitaxel, and weekly paclitaxel single agent as calibrator.
Secondary objectives are:
- pCR rate in the breast and axilla,
- Radiological/clinical objective response rate (ORR), breast conservation rate, disease free survival (DFS), and overall survival (OS), in each treatment arm,
- Safety profiles of study combinations and of the single agent reference treatment,
- Molecular characteristics of the tumor tissue and peripheral blood mononuclear cells (PBMC) and any correlation between the biological activity of the study treatment and the disease outcome.
Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer Female |
Drug: paclitaxel Drug: Iniparib (SAR2405550 -BSI-201) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC) |
- Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review [ Time Frame: at the time of definitive surgery ] [ Designated as safety issue: No ]
- Pathological Complete Response (pCR) rate in the breast and axilla [ Time Frame: at the time of definitive surgery ] [ Designated as safety issue: No ]
- Objective Response Rate(ORR) defined in the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as complete response rate + partial response rate [ Time Frame: at the time of definitive surgery ] [ Designated as safety issue: No ]
- Breast conservation rate [ Time Frame: at the time of definitive surgery ] [ Designated as safety issue: No ]
- Disease Free Survival rate (DFS) [ Time Frame: up to a maximum of 5 years after definitive surgery ] [ Designated as safety issue: No ]
- Overall Survival (OS) [ Time Frame: up to a maximum of 5 years after definitive surgery ] [ Designated as safety issue: No ]
- Safety parameters (number of patients AE, SAE or AEPM) [ Time Frame: up to a maximum of 5 years after definitive surgery ] [ Designated as safety issue: Yes ]
- Molecular-biological testing [ Time Frame: 2 or 3 timepoints during treatment period ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 141 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | February 2017 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: SAR240550 twice weekly/ paclitaxel weekly
SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
|
Drug: Iniparib (SAR2405550 -BSI-201)
Pharmaceutical form : solution for infusion Route of administration :Intravenous |
|
Experimental: SAR240550 weekly/ paclitaxel weekly
SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
|
Drug: Iniparib (SAR2405550 -BSI-201)
Pharmaceutical form : solution for infusion Route of administration :Intravenous |
|
Active Comparator: Paclitaxel alone
Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
|
Drug: paclitaxel
Pharmaceutical form:solution for infusion Route of administration: intravenous |
Detailed Description:
Active study treatment will be given either as twice weekly administration (Day 1 and Day 4) or as weekly administration (Day 1) for a maximum of 24 infusions for Arm A and for a maximum of 12 infusions for Arm B. In all study arms, treatment will be given until definitive surgery, the first sign of disease progression, unacceptable toxicity or withdrawal of patient consent.
Definitive surgery will be performed within 2 to 4 weeks after the last dose of study treatment.
Patients who complete all the study treatment or who withdraw consent or experience intolerable toxicity will undergo surgery according to local practices.
The cut-off date for the primary analyses will be 30 days after the last study treatment administration or the date of the definitive surgery, whichever comes last.
The maximum follow up for each individual patient will be until death or 5 years after the definitive surgery date whatever happens first.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Histologically confirmed Stage II-IIIA invasive breast cancer eligible for definitive surgery and Estrogen Receptor (ER)-negative, Progesterone receptor (PgR)-negative and Human epidermal growth factor receptor 2 (HER2) non-overexpressing by Immunohistochemistry (IHC) (0+, 1+) or fluorescence in situ hybridization (FISH negative, ratio <1.8) or IHC (2+, 3+) /FISH-negative.
- The primary tumor must be > 2cm in diameter measured by physical examination and mammography (mandatory) plus either echography or Magnetic Resonance Imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate bone marrow reserve
- Adequate liver and renal function.
- Age > or = 18 years
Exclusion criteria:
- Any prior treatment for primary breast cancer.
- Bilateral or multicentric breast cancer.
- Other primary tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- Pre-existing peripheral neuropathy grade > or = 2 as per National Cancer Institute Common Toxicity Criteria for Adverse Event (NCI CTCAE) at randomization.
- Any history of medical (e.g., cardiovascular, uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection) or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results
- Pregnancy or breastfeeding women.
- Women of childbearing potential (<2 years after the last menstruation) not using effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug.
- Requirement for radiation therapy concurrent with study anticancer treatment. Patients who require breast or chest wall radiation therapy after surgery are eligible.
- Known hypersensitivity to any of the study drugs or excipients
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations| France | |
| Investigational Site Number 250001 | |
| Besancon Cedex, France, 25030 | |
| Investigational Site Number 250004 | |
| Bordeaux, France, 33076 | |
| Investigational Site Number 250006 | |
| Bron Cedex, France, 69677 | |
| Investigational Site Number 250003 | |
| Paris Cedex 10, France, 75475 | |
| Investigational Site Number 250002 | |
| Toulouse, France, 31052 | |
| Investigational Site Number 250005 | |
| Villejuif, France, 94805 | |
| Germany | |
| Investigational Site Number 276003 | |
| Erlangen, Germany, 91054 | |
| Investigational Site Number 276004 | |
| Hamburg, Germany, 20357 | |
| Investigational Site Number 276002 | |
| Köln, Germany, 50931 | |
| Investigational Site Number 276001 | |
| Mönchengladbach, Germany, 41061 | |
| Spain | |
| Investigational Site Number 724001 | |
| Barcelona, Spain, 08035 | |
| Investigational Site Number 724009 | |
| Cáceres, Spain, 10003 | |
| Investigational Site Number 724013 | |
| Córdoba, Spain, 14004 | |
| Investigational Site Number 724006 | |
| Islas Baleares, Spain, 07014 | |
| Investigational Site Number 724012 | |
| Jaén, Spain, 23007 | |
| Investigational Site Number 724002 | |
| Lérida, Spain, 25198 | |
| Investigational Site Number 724016 | |
| Madrid, Spain, 28041 | |
| Investigational Site Number 724005 | |
| Madrid, Spain, 28033 | |
| Investigational Site Number 724007 | |
| Reus, Spain, 43201 | |
| Investigational Site Number 724018 | |
| Santiago De Compostela, Spain, 15706 | |
| Investigational Site Number 724010 | |
| Sevilla, Spain, 41013 | |
| Investigational Site Number 724017 | |
| Sevilla, Spain, 41009 | |
| Investigational Site Number 724003 | |
| Torrevieja, Spain, 03186 | |
| Investigational Site Number 724011 | |
| Valencia, Spain, 46009 | |
| Investigational Site Number 724015 | |
| Valencia, Spain, 46010 | |
| Study Director: | Clinical Sciences & Operations | Sanofi |
More Information
No publications provided
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT01204125 History of Changes |
| Other Study ID Numbers: | TCD11419, 2010-018960-17 |
| Study First Received: | September 13, 2010 |
| Last Updated: | March 20, 2013 |
| Health Authority: | Spain: Ministry of Health |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Tubulin Modulators |
Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013